Bioaffinity technologies expands diagnostic division with promotions and new hires to strengthen clinical bench

San antonio--( business wire )--bioaffinity technologies, inc. (nasdaq: biaf; biafw), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff.
BIAF Ratings Summary
BIAF Quant Ranking